Academia

Ponatinib also produces an improvement in progression-free survival compared with imatinib among those with Philadelphia chromosome-positive acute lymphoblastic leukemia in the phase 3 PhALLCON trial.

The review summarized existing evidence around short- and long-term treatment-related toxicities among adolescents and young adults (AYAs), as well as gaps in care guidelines for AYA survivors of lymphoma.

Full team coverage from the European Hematology Association 2023 Hybrid Congress, which took place June 8-11 in Frankfurt, Germany.

Polymyalgia rheumatica (PMR) is an inflammatory disease often misdiagnosed as certain cancers, among other diseases. Researchers have recently made progress to better diagnose PMR using a standard uptake value index based on fluorodeoxyglucose with positron-emission tomography/computed tomography.

A review identified specificities that suggested that infections of respiratory syncytial virus (RSV) evolve chest tomography features.

Presentation of the COMMANDS trial offered practice-changing results for luspatercept.

Results include a landmark study that involved seamless collaboration across adult and pediatric patient groups, leading to a highly diverse study population. Other coverage addresses access to novel therapies and what's coming in the pipeline, including CAR T-cell therapy with tyrosine kinase inhibitors.

Coverage of addresses by ASCO President Eric P. Winer, MD, and National Cancer Institute Director Monica M. Bertagnolli, MD, who is a former ASCO president.

New research suggests that when cancer cells are under stress, cellular chaperone protein GRP78 alters its behavior and migrates to the cell's nucleus, where it modifies gene activities and allows cancer cells to become more mobile and invasive.

Gene therapy is only one exciting area of treatments in the pipeline to potentially treat inherited retinal disease, said Byron L. Lam, MD, professor of ophthalmology, University of Miami Miller School of Medicine's Bascom Palmer Eye Institute.

The most exciting treatment for inherited retinal disease was approved in 2017, but there are many novel treatments in phase 2 or phase 3 trials at this point, said Byron L. Lam, MD, professor of ophthalmology, University of Miami Miller School of Medicine's Bascom Palmer Eye Institute.

The successful collaboration between a primary care–based network of practices and academic researchers demonstrates feasibility and the need for more funding for primary care research.

Insurance is by far the most important factor of whether patients followed up with treatment after getting screened for glaucoma, said Byron L. Lam, MD, professor of ophthalmology, University of Miami Miller School of Medicine's Bascom Palmer Eye Institute.

Natalie S. Callander, MD, director of the University of Wisconsin Carbone Cancer Center Myeloma Clinical Program, reviewed the treatment landscape at the National Comprehensive Cancer Network (NCCN) 2023 Annual Conference.

Many people often don’t connect the dots between climate change and its impact on skin health, but these effects have been happening for years, said Eva R. Parker, MD, associate professor of dermatology at Vanderbilt University Medical Center.

The findings, published in the Journal of the National Comprehensive Cancer Network, add to the evidence that the shift to precision medicine is built on data that have not included sufficient numbers of patients of color.

Seeking to speed up the execution of evidence-based care practices, the Patient-Centered Outcomes Research Institute (PCORI) announced the 42 health systems across the country who will join a 5-year program to build capacity and implementation to improve health care outcomes.

The 72nd American College of Cardiology Scientific Session Together With the World Congress of Cardiology (ACC.23/WCC), runs from Saturday to Monday in New Orleans, Louisiana.

While the current therapies are effective for treating branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO), they are inadequate for long-term treatment in clinical practice, according to an analysis of real-world data.

Two studies looking at a higher dose of aflibercept found that an 8-mg dose can be maintained at longer dosing intervals with similar benefits and no additional safety signals compared with the 2-mg dose.

Much of the evidence that has been used to base current standard of care for diabetic eye diseases stems from studies performed by the DRCR Retina Network over the years.

Home optical coherence tomography (OCT) has shown there is a wide degree of heterogeneity in fluid dynamics and treatment response that may not be clear during regular office visits and scans. Presenters reviewed the latest data in home OCT to manage wet age-related macular degeneration (AMD).